文献速递白血病

Magrolimab联合阿扎胞苷对比医生选择方案治疗初治TP53突变急性髓系白血病:ENHANCE-2研究

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
PubMed 文献 · Blood · 2025-01-01

ENHANCE-2是一项全球随机3期试验,评估抗CD47单抗Magrolimab联合阿扎胞苷(Magro/Aza)对比医生选择方案治疗初治TP53突变急性髓系白血病。不适合强化治疗者随机接受Magro/Aza或维奈克拉联合阿扎胞苷(Ven/Aza);适合强化治疗者随机接受Magro/Aza或7+3诱导化疗。中期分析时非强化臂OS的HR为1.191(95%CI 0.744-1.906),达到无效性定义而终止研究;最终分析未达到主要终点。

要点

  • 非强化臂Magro/Aza组中位OS 4.4个月 vs 对照组6.6个月(HR 1.132;95%CI 0.783-1.637;P=0.5070)。
  • 强化臂Magro/Aza组中位OS 7.3个月 vs 对照组11.1个月(HR 1.434;95%CI 0.635-3.239;P=0.3798)。
  • ENHANCE-2未达到TP53突变AML的主要OS终点,但为未来研究提供了重要数据。

核心结论

  • ENHANCE-2未达到TP53突变急性髓系白血病的主要OS终点,但为这一难治人群的未来研究提供了重要数据。

研究设计与样本

  • 全球、随机、3期ENHANCE-2试验,评估Magro/Aza对比医生选择方案治疗初治TP53突变AML。
  • 不适合强化治疗者随机接受Magro/Aza或Ven/Aza(非强化臂);适合强化治疗者随机接受Magro/Aza或7+3诱导化疗(强化臂)。
  • 主要终点为非强化臂的总生存期(OS)。
  • 试验注册号:NCT04778397。

主要发现

  • 中期分析时非强化臂两组间OS的HR为1.191(95%CI 0.744-1.906),达到研究无效性定义,研究终止。
  • 最终分析非强化臂(n=205)Magro/Aza组 vs 对照组中位OS为4.4 vs 6.6个月(HR 1.132;95%CI 0.783-1.637;P=0.5070)。
  • 最终分析强化臂(n=52)Magro/Aza组 vs 对照组中位OS为7.3 vs 11.1个月(HR 1.434;95%CI 0.635-3.239;P=0.3798)。
  • ≥3级不良事件发生率Magro/Aza组与对照组相似:非强化臂(n=194)分别为96.9%和95.9%;强化臂(n=50)分别为92.6%和95.7%。
  • ≥3级贫血发生率:非强化臂Magro/Aza组27.1% vs 对照组23.5%;强化臂Magro/Aza组25.9% vs 对照组21.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with TP53-mutated acute myeloid leukemia (AML) have an extremely poor prognosis, necessitating new treatments. The global, randomized, phase 3 ENHANCE-2 trial evaluated the anti-CD47 monoclonal antibody magrolimab plus azacitidine (Magro/Aza) for previously untreated TP53-mutated AML. Patients determined ineligible for intensive therapy were randomized to receive Magro/Aza or venetoclax plus Aza (Ven/Aza); those eligible for intensive therapy were randomized to receive Magro/Aza or 7+3 induction chemotherapy. The primary end point was overall survival (OS) in the nonintensive arm. At interim analysis, nonintensive-arm OS hazard ratio (HR) between treatment groups was 1.191 (95% confidence interval [CI], 0.744-1.906), meeting the study's definition for futility and resulting in study termination. At final analysis, median OS was 4.4 vs 6.6 months (HR, 1.132; 95% CI, 0.783-1.637; P = .5070) in the nonintensive arm (n = 205) and 7.3 vs 11.1 months (HR, 1.434; 95% CI, 0.635-3.239; P = .3798) in the intensive arm (n = 52) between Magro/Aza and control groups, respectively. Incidences of grade ≥3 adverse events were similar across Magro/Aza and control groups (nonintensive, n = 194: 96.9% and 95.9%; intensive, n = 50: 92.6% and 95.7%), including grade ≥3 anemia (nonintensive: 27.1% and 23.5%; intensive: 25.9% and 21.7%). Grade ≥3 infections were observed in 50.0% and 53.1% of patients in the nonintensive arm and 44.4% and 65.2% of intensive-arm patients. ENHANCE-2 did not meet its primary end point of OS in TP53-mutated AML but provides important data informing future studies in this challenging population. This trial was registered at www.clinicaltrials.gov as #NCT04778397.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Zeidner JF, Sallman DA, Récher C, et al. Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025. PMID: 40009500. doi:10.1182/blood.2024027408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。